Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Does using fidaxomicin to treat Clostridium difficile infection (CDI) reduce the recovery of C. difficile from faeces, patient's skin and the immediate environment compared to treatment with vancomycin or metronidazole?

Next Previous
Trial Profile

Does using fidaxomicin to treat Clostridium difficile infection (CDI) reduce the recovery of C. difficile from faeces, patient's skin and the immediate environment compared to treatment with vancomycin or metronidazole?

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 13 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fidaxomicin (Primary) ; Metronidazole; Vancomycin
  • Indications Clostridium difficile infections
  • Focus Therapeutic Use

    • Most Recent Events

    • 08 Sep 2021 Status changed from active, no longer recruiting to completed.
    • 16 Apr 2019 Results assessing efficacy of Fidaxomicin in patients with Clostridium difficile infections, presented at the 29th European Congress of Clinical Microbiology and Infectious Diseases
    • 03 Dec 2015 Accrual to date is 116% according to United Kingdom Clinical Research Network.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top